Overview Covering developments across all frontiers of T1D R&D, including immunotherapy, beta cell regeneration, manufactured cell therapy, and AID For decades, insulin has been a lifeline — but not a cure. Nine and a half million people worldwide live with type 1 diabetes (T1D), facing not only the worry and expense of managing the disease but the risks of hypoglycemia and complications.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Greg
Contact Greg, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack